RNAi compound targeted to thrombospondin-1 and applications thereof

貢獻的翻譯標題: 第一型血小板活化素siRNA分子及其應用

Ming-Derg Lai (Inventor)

研究成果: Patent

摘要

The present invention relates to an RNAi compound and an expression plasmid for inhibiting expression of Thrombospondin-1, which comprises a target sequence selected from Thrombospondin-1 gene. The present invention also related to a pharmaceutical composition comprising the RNAi compound and applications thereof. The RNAi compound can reduce the expression of Thrombospondin-1 to activate immune responses.
原文English
專利號8377902
出版狀態Published - 2011 七月 7

指紋

Thrombospondin 1
RNA Interference
Plasmids
Pharmaceutical Preparations
Genes

引用此文

@misc{dae59b57bba648039c3267907500af77,
title = "RNAi compound targeted to thrombospondin-1 and applications thereof",
abstract = "The present invention relates to an RNAi compound and an expression plasmid for inhibiting expression of Thrombospondin-1, which comprises a target sequence selected from Thrombospondin-1 gene. The present invention also related to a pharmaceutical composition comprising the RNAi compound and applications thereof. The RNAi compound can reduce the expression of Thrombospondin-1 to activate immune responses.",
author = "Ming-Derg Lai",
year = "2011",
month = "7",
day = "7",
language = "English",
type = "Patent",
note = "8377902",

}

TY - PAT

T1 - RNAi compound targeted to thrombospondin-1 and applications thereof

AU - Lai, Ming-Derg

PY - 2011/7/7

Y1 - 2011/7/7

N2 - The present invention relates to an RNAi compound and an expression plasmid for inhibiting expression of Thrombospondin-1, which comprises a target sequence selected from Thrombospondin-1 gene. The present invention also related to a pharmaceutical composition comprising the RNAi compound and applications thereof. The RNAi compound can reduce the expression of Thrombospondin-1 to activate immune responses.

AB - The present invention relates to an RNAi compound and an expression plasmid for inhibiting expression of Thrombospondin-1, which comprises a target sequence selected from Thrombospondin-1 gene. The present invention also related to a pharmaceutical composition comprising the RNAi compound and applications thereof. The RNAi compound can reduce the expression of Thrombospondin-1 to activate immune responses.

M3 - Patent

M1 - 8377902

ER -